GlassScriptPhysician profile
Safa Maqbul Shaikh
NPI 1679816946
$1,049.31
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $21.95 · 2021: $91.53 · 2022: $420 · 2023: $211 · 2024: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $405.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $109.97 | 2019 | |
| Amgen INC. | $108.05 | 2022 | |
| Emd Serono, INC. | $105.37 | 2022-2024 | Mavenclad |
| Jazz Pharmaceuticals INC. | $91.44 | 2022 | |
| Abbvie INC. | $82.67 | 2022-2024 | Botox |
| Lundbeck LLC | $77.27 | 2022-2023 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $72.56 | 2021-2024 | Ajovy |
| Ucb, INC. | $63.44 | 2021-2023 | Briviact, Fintepla |
| Ipsen Biopharmaceuticals, INC | $54.90 | 2022-2023 | Dysport |
| Merz Pharmaceuticals, LLC | $41.15 | 2023 | Xeomin |
| Scilex Pharmaceuticals INC. | $33.68 | 2023-2024 | Ztlido |
| Avanir Pharmaceuticals, INC. | $25.13 | 2022 | |
| Viiv Healthcare Company | $21.95 | 2020 | |
| Grifols USA, LLC | $21.75 | 2024 | Gamunex-C |
| Biohaven Pharmaceutical Holding Company LTD. | $20.96 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $20.77 | 2024 | |
| Optinose US, INC. | $19.07 | 2022 | |
| Tg Therapeutics, INC. | $18.50 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $17.33 | 2021 | |
| Merck Sharp & Dohme LLC | $16.75 | 2021 | |
| Neurocrine Biosciences, INC. | $14.70 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Safa Shaikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.